Pulse Biosciences Inc(PLSE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.17 | Insider Own | 73.22% | Shs Outstand | 70.8M | Perf Week | -2.92% |
| Market Cap | 3.79B | Forward P/E | - | EPS next Y | -5.48% | Insider Trans | 1.32% | Shs Float | 19.1M | Perf Month | 22.6% |
| Enterprise Value | 3.69B | PEG | - | EPS next Q | -0.32 | Inst Own | 15.31% | Short Float | 16.34% | Perf Quarter | 97.51% |
| Income | -0.08B | P/S | 3183.15 | EPS this Y | -58.34% | Inst Trans | 29.93% | Short Ratio | 6.87 | Perf Half Y | 149.34% |
| Sales | 0.00B | P/B | 37.79 | EPS next 5Y | -9.89% | ROA | -67.9% | Short Interest | 3.12M | Perf YTD | 286.82% |
| Book/sh | 1.41 | P/C | 37.28 | EPS past 3/5Y | 14.44% 12.82% | ROE | -78.49% | 52W High | -9.83% ($58.90) | Perf Year | 251.72% |
| Cash/sh | 1.42 | P/FCF | - | Sales past 3/5Y | -20.63% - | ROIC | -76.55% | 52W Low | 322.85% ($12.56) | Perf 3Y | 1044.61% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -11.31% | Gross Margin | -43.21% | Volatility(W/M) | 10.79% 7.34% | Perf 5Y | 155.83% |
| Dividend TTM | - | EV/Sales | 3103.44 | Sales Y/Y TTM | - | Oper. Margin | -7007.76% | ATR (14) | 3.94 | Perf 10Y | 785.17% |
| Dividend Ex-Date | - | Quick Ratio | 9.61 | EPS Q/Q | -25.06% | Profit Margin | -6755.78% | RSI (14) | 63.01 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.63 | Sales Q/Q | - | SMA20 | 6.5% ($49.87) | Beta | 1.55 | Target Price | $50.8 |
| Payout | - | Debt/Eq | 0.07 | Earnings | 2026/8/6 | SMA50 | 33.21% ($39.87) | Rel Volume | 1.46 | Prev Close | $54.43 |
| Employees | 116 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | 8.23% -13.2% | SMA200 | 113.58% ($24.87) | Avg Volume(3M) | 0.45M | Price | $53.11 |
| IPO | 2016/5/18 | Option/Short | Yes/Yes | Trades | 8987 | Volume | 664,127 | Change | -2.43% |
Company
PLSE is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
⚡ A U.S. medical device company developing equipment that leverages nanosecond pulsed electric field (nsPEF) technology. Using its proprietary technology that eliminates targeted cells through brief electrical pulses, the company develops medical devices aimed at treating cardiac arrhythmias and skin conditions, and is pushing toward commercialization. As a developer of medical devices built around the differentiated nsPEF technology, the stock's performance hinges heavily on progress in clinical trials and commercialization milestones.
Over the past 1 year, on the higher side
10% below its 1-year high.
PLSE has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -58.3% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +1044.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 15.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
XHE 0.01%
ISMD 0.00%
IWC 0.00%
ESSC 0.00%
BTR 0.00%It ranks #4 in the industry
Based on market cap of $4B.
PLSE $4B PER -
ISRG $131B PER 42.4
BDX $48B PER 53.6
MDLN $43B PER 38.1
FAQ
What kind of company is PLSE?
PLSE belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of PLSE?
The market cap of PLSE is approximately $3.8B, ranking 1,601 within its sector.
What is the 52-week high and low for PLSE?
PLSE has recorded a 52-week high of $58.90 and a low of $12.56.
